5 Biotechs With Prostate Cancer Treatments Worth Watching

Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.

Apr 5, 2014 at 5:30PM

In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to recently released statistics from the American Cancer Society -- although it lags behind lung, liver, stomach, colorectal, and oesophageal cancer globally.

Prostate cancer cases have also been increasing markedly since the 1970s, although this trend could be a statistical artifact from a concomitant increase in screening rates. Put simply, more men began getting screened in the 1990s, potentially leading to a higher detection rate. Indeed, incidence rates are known to be significantly higher in Western countries, where regular screenings are common, compared to developing nations.

What's important to understand from an investing perspective is that the global prostate cancer market is presently valued at over $26 billion, and this figure is expected to rise to over $50 billion as soon as 2017. Consequently, we have seen several new prostate cancer drugs hit the market over the past four years, with dozens of others entering clinical trials. So let's take a deeper look at five biotechs leading this wave of new innovation.  

New generation of commercially available therapeutics
Johnson & Johnson's (NYSE:JNJ) hormome therapy Zytiga, developed by its subsidiary Janssen Biotech, was approved by the U.S. Food and Drug Administration, or FDA, in 2011. Zytiga is indicated as a treatment for castration-resistant metastatic prostate cancer and works by blocking androgen production -- a common therapeutic target among prostate cancer hormone therapies in general.  Zytiga is now a market leader among prostate cancer drugs, raking in $1.7 billion in sales in 2013. That said, Medivation and Astellas Pharma's hormone therapy Xtandi, approved in 2012, appears to be cutting into Zytiga's double-digit sales growth. Time will tell how this head to head competition plays out. 


Source: Prostate.net

Dendreon's (NASDAQ:DNDN) personalized prostate cancer vaccine Provenge became commercially available in 2010 for the treatment of asymptomatic or minimally symptomatic, castration-resistant metastatic prostate cancer. The drug has struggled to gain market share, and sales have been particularly rocky since the approvals of Xtandi and Zytiga. On the bright side, Dendreon will launch Provenge in Europe this year, which could help boost sales.


Source: urosciences.com

In 2013, the FDA approved Bayer Pharmaceuticals(NASDAQOTH:BAYRY) radium isotope Xofigo as a treatment for men with prostate cancer that has spread to their bones and have stopped responding to hormone therapy. Clinical studies showed that Xofigo extended life span by three months on average, but some countries have balked at covering the drug because of its considerable cost. As a more specialized drug, Xofigo probably won't see the eye-popping sales numbers of Zytiga, but the drug could be a decent revenue earner in its own right due to the sheer size of the prostate cancer market. 

Clinical products to watch
On the clinical front, there are several promising therapies under development. For instance, the DNA-based vaccine-maker Inovio Pharmaceuticals (NASDAQ:INO) is developing a prostate cancer vaccine dubbed "INO-5150," currently at the preclinical stage of development. INO-5150 is another immunotherapy approach, but the biological mechanism is entirely different from Provenge.

Seattle Genetics (NASDAQ:SGEN) is teaming up with Progenics Pharmaceuticals, among others, to develop antibody drug conjugates, or ADCs, to treat prostate cancer. Seattle Genetics has both an early and mid-stage ADC under development for prostate cancer. The mid-stage candidate has faced some setbacks because of toxicity issues, which may hinder further development. Overall, it's important to bear in mind that this is only a small sampling of the clinical candidates for prostate cancer.

Foolish wrap-up
Prostate cancer has become an epidemic for men in the U.S., and the new generation of therapies could radically change the standard of care for this disease. Currently, Zytiga is locked in a fierce battle with Xtandi for the front-runner position, but Provenge has also seen sales grow modestly recently. In my view, this dynamic market shows that doctors are experimenting with their new found options, keeping any one drug from gaining a stranglehold on the market. Looking ahead, the continued growth of the prostate cancer market suggests there is ample room for even more new therapies. As such, you may want to dig deeper into these five biotechs helping to fight the battle against prostate cancer. 

3 stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Editor's Note: A previous version of this article did not mention that Astellas Pharma is Medivation's partner on the drug Xtandi. The Fool regrets the error.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Seattle Genetics and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers